TY - JOUR
T1 - The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
AU - Cogdill, Alexandria P.
AU - Gaudreau, Pierre Olivier
AU - Arora, Reetakshi
AU - Gopalakrishnan, Vancheswaran
AU - Wargo, Jennifer A.
N1 - Funding Information:
J.A.W. is supported by the NIH ( 1 R01 CA219896-01A1 ), US-Israel Binational Science Foundation ( 201332 ), Kennedy Memorial Foundation ( 0727030 ), the Melanoma Research Alliance ( 4022024 ), American Association for Cancer Research Stand Up To Cancer ( SU2C-AACR-IRG-19-17 ), Department of Defense ( W81XWH-16-1-0121 ), MD Anderson Cancer Center Multidisciplinary Research Program Grant, Andrew Sabin Family Fellows Program, and MD Anderson Cancer Center’s Melanoma Moon Shots Program. J.A.W. is a member of the Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center. P.O.G is supported by the Fonds de Recherche Québec–Santé’s (FRQS) Resident Physician Health Research Career Training Program (32667). A.P.C. is supported by the Schissler Foundation and the American Legion Auxiliary Department of Texas.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/11
Y1 - 2018/11
N2 - The human microbiome is a complex aggregate of microorganisms, and their genomes exert a number of influences crucial to the metabolic, immunologic, hormonal, and homeostatic function of the host. Recent work, both in preclinical mouse models and human studies, has shed light on the impact of gut and tumor microbiota on responses to systemic anticancer therapeutics. In light of this, strategies to target the microbiome to improve therapeutic responses are underway, including efforts to target gut and intratumoral microbes. Here, we discuss mechanisms by which microbiota may impact systemic and antitumor immunity, in addition to outstanding questions in the field. A deeper understanding of these is critical as we devise putative strategies to target the microbiome.
AB - The human microbiome is a complex aggregate of microorganisms, and their genomes exert a number of influences crucial to the metabolic, immunologic, hormonal, and homeostatic function of the host. Recent work, both in preclinical mouse models and human studies, has shed light on the impact of gut and tumor microbiota on responses to systemic anticancer therapeutics. In light of this, strategies to target the microbiome to improve therapeutic responses are underway, including efforts to target gut and intratumoral microbes. Here, we discuss mechanisms by which microbiota may impact systemic and antitumor immunity, in addition to outstanding questions in the field. A deeper understanding of these is critical as we devise putative strategies to target the microbiome.
KW - cancer
KW - immunotherapy
KW - microbiome
UR - http://www.scopus.com/inward/record.url?scp=85055249042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055249042&partnerID=8YFLogxK
U2 - 10.1016/j.it.2018.09.007
DO - 10.1016/j.it.2018.09.007
M3 - Review article
C2 - 30392721
AN - SCOPUS:85055249042
SN - 1471-4906
VL - 39
SP - 900
EP - 920
JO - Trends in Immunology
JF - Trends in Immunology
IS - 11
ER -